Boos Amends Lexaria Bioscience Ownership Filing
Ticker: LEXX · Form: SC 13D/A · Filed: Feb 14, 2024
Sentiment: neutral
Topics: insider-filing, ownership-change, amendment, beneficial-ownership
TL;DR
**Big shareholder Boos just updated his stake in Lexaria Bioscience, signaling a change in his position or plans!**
AI Summary
Wayne W. Boos filed an Amendment No. 1 to Schedule 13D (SC 13D/A) on February 14, 2024, regarding his beneficial ownership in Lexaria Bioscience Corp. common stock. The event triggering this amendment occurred on December 31, 2023. The filing indicates a change in ownership or intent, but specific share counts or dollar amounts related to the transaction are not detailed in this excerpt.
Why It Matters
An amended Schedule 13D signals a change in a significant shareholder's stake or investment intent, which can influence market perception and the company's strategic direction.
Risk Assessment
Risk Level: medium — An amended 13D indicates a change in beneficial ownership or intent by a significant holder, which can introduce uncertainty or signal potential future actions for the company.
Key Numbers
- $0.001 — Par Value (Par value of Lexaria Bioscience Corp. Common Stock)
Key Players & Entities
- Lexaria Bioscience Corp. (company) — Subject Company
- Boos Wayne W (person) — Filing Person
- Robert B. Goldberg, Esq. (person) — Authorized to Receive Notices
FAQ
Who filed this SC 13D/A?
The SC 13D/A was filed by Boos Wayne W.
What is the subject company of this filing?
The subject company is Lexaria Bioscience Corp.
What is the CUSIP number for the securities involved?
The CUSIP number for the Common Stock is 52886N.
What was the date of the event which required this filing?
The date of the event which required this filing was December 31, 2023.
Who is authorized to receive notices and communications for this filing?
Robert B. Goldberg, Esq. is authorized to receive notices and communications.
Filing Details
This Form SC 13D/A (Form SC 13D/A) was filed with the SEC on February 14, 2024 by Boos Wayne W regarding Lexaria Bioscience Corp. (LEXX).